Jung Eun Kyung, Jin Seong-Min, Kim Jae-Gu, Jung Jae-Uk, Lee Dong Hoon, Lee Joon Kyoo, Lim Sang Chul, Chung Woong-Ki, Kim Hee Kyung, Hwang Jun-Eul, Shim Hyun-Jeong, Bae Woo-Kyun, Cho Sang-Hee, Chung Ik-Joo, Yoon Tae Mi
Department of Otorhinolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Jeollanam 519-763, Republic of Korea.
Department of Radiation Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Jeollanam 519-763, Republic of Korea.
Oncol Lett. 2020 Jul;20(1):921-930. doi: 10.3892/ol.2020.11628. Epub 2020 May 14.
Early [stage I and II (T2N0M0)] laryngeal cancer types are currently recommended to be treated with a single modality, consisting of definitive radiation therapy or larynx-preserving surgery. Although the treatment outcomes of stage I are good, the frequency of successful outcomes decreases with T2N0M0. Therefore, the present study investigated the treatment outcomes of different treatment methods in T2N0M0 laryngeal cancer. In total, 83 patients with previously untreated T2N0M0 laryngeal squamous cell carcinoma were enrolled. Patients were grouped by treatment method: Radiation therapy (RT; 27 patients); chemoradiotherapy (CRT; 46 patients) with cisplatin base; and surgery-based therapy (SBT; ten patients). The recurrence rates of the RT, CRT and SBT groups were 44.4, 19.6 and 50%, respectively. Moreover, the local control rates of the RT, CRT and SBT groups were 55.6, 87.0 and 80%, respectively. The CRT group had a significantly lower recurrence rate and higher local control rate compared with the RT group (P<0.05). In the survival analysis, overall and disease-specific survival rate did not differ significantly among the treatment groups. However, 3- and 5-year disease-free survival rates (DFS) of the RT group were both 55%, those of the SBT group were both 50% and those of the CRT group were both 80%. Furthermore, the DFS was significantly higher in CRT group compared with the other groups (P=0.02). Using multivariate analysis with Cox regression, it was found that the treatment method was the most important factor for DFS and had a significant impact in the CRT group. In addition, in patients with glottic cancer with anterior commissure and subglottic invasion, the CRT group had significantly improved DFS compared with the RT group, whereas there was no significant difference between the two groups in patients without subglottic invasion. According to National Cancer Institution Common Toxicity Criteria (version 5.0), more patients had toxicity in the CRT group compared with the RT group. However, in the RT and CRT groups, no patients demonstrated mortality due to toxicity, and treatment-related toxicities were manageable. Collectively, although definitive conclusions could not be established, due to the limitations of this retrospective study, the results suggest that CRT had a positive impact on the local control and DFS rates with manageable toxicity in patients with T2N0M0 laryngeal cancer.
目前建议对早期[I期和II期(T2N0M0)]喉癌采用单一治疗方式,包括根治性放射治疗或保喉手术。虽然I期的治疗效果良好,但T2N0M0患者的成功治疗频率会降低。因此,本研究调查了不同治疗方法对T2N0M0喉癌的治疗效果。总共纳入了83例未经治疗的T2N0M0喉鳞状细胞癌患者。患者按治疗方法分组:放射治疗(RT;27例患者);以顺铂为基础的放化疗(CRT;46例患者);以及手术为主的治疗(SBT;10例患者)。RT、CRT和SBT组的复发率分别为44.4%、19.6%和50%。此外,RT、CRT和SBT组的局部控制率分别为55.6%、87.0%和80%。与RT组相比,CRT组的复发率显著降低,局部控制率更高(P<0.05)。在生存分析中,各治疗组的总生存率和疾病特异性生存率无显著差异。然而,RT组的3年和5年无病生存率(DFS)均为55%,SBT组均为50%,CRT组均为80%。此外,CRT组的DFS显著高于其他组(P=0.02)。通过Cox回归进行多因素分析发现,治疗方法是DFS的最重要因素,对CRT组有显著影响。此外,在伴有前联合和声门下侵犯的声门癌患者中,与RT组相比,CRT组的DFS显著改善,而在无 声门下侵犯的患者中,两组之间无显著差异。根据美国国立癌症研究所通用毒性标准(第5.0版),与RT组相比,CRT组有更多患者出现毒性反应。然而,在RT组和CRT组中,没有患者因毒性反应死亡,且与治疗相关的毒性反应是可控的。总体而言,尽管由于本回顾性研究的局限性无法得出明确结论,但结果表明,CRT对T2N0M0喉癌患者的局部控制率和DFS率有积极影响,且毒性反应可控。